ID   AR
AC   CVCL_E6X9
RX   PubMed=9384677;
RX   PubMed=12836015;
RX   PubMed=15365776;
CC   HLA typing: A*03,03; B*07,51; DQB1*06:02,06:03; DRB1*13:01,15:01:01 (PubMed=12836015).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=12836015; DOI=10.1007/s00432-003-0445-7;
RA   Kayser, Simone
RA   Watermann, Iris
RA   Rentzsch, Christine
RA   Weinschenk, Toni
RA   Wallwiener, Diethelm
RA   Guckel, Brigitte
RT   "Tumor-associated antigen profiling in breast and ovarian cancer:
RT   mRNA, protein or T cell recognition?";
RL   J. Cancer Res. Clin. Oncol. 129:397-409(2003).
//
RX   PubMed=9384677;
RA   Guckel, Brigitte
RA   Lindauer, Markus
RA   Rudy, Wolfgang
RA   Habicht, Annette
RA   Siebels, Michael
RA   Kaul, Sepp
RA   Bastert, Gunther
RA   Meuer, Stefan Carl
RA   Moebius, Ulrich
RT   "CD80-transfected human breast and ovarian tumor cell lines: improved
RT   immunogenicity and induction of cytolytic CD8+ T lymphocytes.";
RL   Cytokines Mol. Ther. 1:211-221(1995).
//
RX   PubMed=15365776; DOI=10.1007/s00262-004-0583-z; PMCID=PMC11034349;
RA   Guckel, Brigitte
RA   Stumm, Susanne
RA   Rentzsch, Christine
RA   Marme, Alexander
RA   Mannhardt, Geeske
RA   Wallwiener, Diethelm
RT   "A CD80-transfected human breast cancer cell variant induces
RT   HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as
RT   well as in vivo.";
RL   Cancer Immunol. Immunother. 54:129-140(2005).
//